Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7

Cancer Genetics

Volumn 208, Issue 3, 2015, Pages 85-90

  Takeoka, Kayo ^a   Okumura, Atsuko ^a   Maesako, Yoshitomo ^a   Akasaka, Takashi ^a   Ohno, Hitoshi ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

AML with inv(2)(p23q13) RANBP2 ALK and monosomy 7; Crizotinib resistance; Del(1)(p13p22); P.G1269A mutation

Indexed keywords

ALANINE; ANAPLASTIC LYMPHOMA KINASE; BINDING PROTEIN; CRIZOTINIB; CYTARABINE; DAUNORUBICIN; GLYCINE; RAN BINDING PROTEIN 2; UNCLASSIFIED DRUG; CHAPERONE; HYBRID PROTEIN; NUCLEOPORIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RAN-BINDING PROTEIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RECURRENCE; CASE REPORT; CHROMOSOME 1P; CHROMOSOME 2P; CHROMOSOME 2Q; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME G BAND; CHROMOSOME INVERSION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HETEROZYGOSITY; HUMAN; HUMAN CELL; KARYOTYPING; MALE; MOLECULAR PROBE; MONOSOMY 7; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; CHROMOSOME 2; CHROMOSOME 7; DRUG RESISTANCE; FEMALE; GENETICS; LEUKEMIA, MYELOID, ACUTE;

AGED; CHROMOSOME DELETION; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 7; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR CHAPERONES; NUCLEAR PORE COMPLEX PROTEINS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS;

EID: 84928210362     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2015.01.003     Document Type: Article

References (19)

1. Marino-Enriquez A., Dal Cin P. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genet 2013, 206:357-373.
2. Hallberg B., Palmer R.H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013, 13:685-700.
3. Malik S.M., Maher V.E., Bijwaard K.E., et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014, 20:2029-2034.
4. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. NEngl J Med 2010, 363:1693-1703.
5. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
6. Gainor J.F., Shaw A.T. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. JClin Oncol 2013, 31:3987-3996.
7. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. JClin Oncol 2013, 31:1105-1111.
8. Maesako Y., Izumi K., Okamori S., et al. inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman. Int J Hematol 2014, 99:202-207.
9. ISCN 2013: an international system for human cytogenetic nomenclature 2013, Karger, Basel. L.G. Shaffer, J. McGowan-Jordan, M. Schmid (Eds.).
10. Maesako Y., Okumura A., Takeoka K., et al. Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia. Leukemia 2014, 28:1935-1937.
11. Chen Y., Takita J., Choi Y.L., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
12. Doebele R.C., Pilling A.B., Aisner D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
13. Choi Y.L., Soda M., Yamashita Y., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. NEngl J Med 2010, 363:1734-1739.
14. Zhang S., Wang F., Keats J., et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011, 78:999-1005.
15. Sasaki T., Okuda K., Zheng W., et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010, 70:10038-10043.
16. Rottgers S., Gombert M., Teigler-Schlegel A., et al. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia 2010, 24:1197-1200.
17. Lim J.H., Jang S., Park C.J., et al. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. Cancer Genet 2014, 207:40-45.
18. Shaw A.T., Kim D.W., Mehra R., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. NEngl J Med 2014, 370:1189-1197.
19. Sakamoto H., Tsukaguchi T., Hiroshima S., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.